• Home
  • Search Results

Search Results

Young Adult (18-34)
Cancer - Leukemia
67 studies match your search
By physician referral or invitation only

cGVHD study

Collecting data on chronic GVHD instances

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
  • Immune System/Infections
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Social Intervention for young adults with cancer

we will be conducting 60-minute interviews with young adults to hear about social connections (in person and online) and cancer support on social media

Age & Gender
  • 22 years ~ 39 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 20 more)
Visit Location
100% Remote (online, phone, text)
Not currently enrolling

Leukemia

The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

ACCL1931 - Levocarnitine as Prophylaxis for Hepatotoxicity in AYA (15-39.9) with de novo ALL/Lly/MPAL

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).

Age & Gender
  • 15 years ~ 39.9 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pediatric Cancers, Leukemia)
  • Kidneys and Liver
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

A study to test if the addition of Inotuzumab Ozogamicin (InO) to standard chemotherapy treatment in patients diagnosed with National Cancer Institute (NCI) High-Risk (HR) B-cell Acute Lymphoblastic Leukemia (B-ALL) or NCI Standard-Risk (SR) B- ALL with high risk features improves outcomes.

To find out if the addition of 2 blocks of inotuzumab ozogamicin to the standard chemotherapy regimen will improve outcomes in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).

Age & Gender
  • 1 years ~ 24 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

UNC Cancer Radiation Therapy Registry

The purpose of this study is to create a registry that will collect clinical data from participants attending UNC Hospitals who may present with metastatic cancer and are evaluated to receive radiation therapy. We hope to create a registry that future studies can pull from to study the impacts of radiation therapy on patient cancer outcomes.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

EXAMINING CANCER-RELATED FATIGUE PREVALENCE AND CONTRIBUTORS OF PERFORMANCE FATIGABILITY AMONG FIREFIGHTERS IN CANCER REMISSION

The overall objective of this project is to examine differences in performance fatigability and contributing mechanisms between firefighters in cancer remission and healthy firefighter controls. Findings from this research project will inform future interventions to reduce CRF in firefighters in cancer remission.

Age & Gender
  • 18 years ~ 55 years
  • Male, Female
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 17 more)
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research